Patents by Inventor Gurdip Bhalay

Gurdip Bhalay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Meta tyrosine derivatives as rho-kinase inhibitors
    Patent number: 11725007
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are meta tyrosine derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: August 15, 2023
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Christine Edwards, Gurdip Bhalay, Patrizia Tisselli
  • Tyrosine analogues derivatives as Rho-kinase inhibitors
    Patent number: 11147812
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are tyrosine analogues derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: October 19, 2021
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Alessandro Accetta, Anna Maria Capelli, Fabio Rancati, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume, Christine Edwards, Patrizia Tisselli
  • TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS
    Publication number: 20210284639
    Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are bicyclic dihydropyrimidine-carboxamide derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: July 12, 2019
    Publication date: September 16, 2021
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Anna Maria CAPELLI, David Edward CLARK, Patrizia TISSELLI, Christine EDWARDS, Amaud Jean Francois Auguste CHEGUILLAUME, Gurdip BHALAY
  • Tyrosine amide derivatives as Rho-Kinase inhibitors
    Patent number: 10954236
    Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: March 23, 2021
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume
  • TYROSINE ANALOGUES DERIVATIVES AS RHO-KINASE INHIBITORS
    Publication number: 20210023080
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are tyrosine analogues derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: September 5, 2018
    Publication date: January 28, 2021
    Inventors: Alessandro ACCETTA, Anna Maria CAPELLI, Fabio RANCATI, Gurdip BHALAY, Arnaud Jean Francois Auguste CHEGUILLAUME, Christine EDWARDS, Patrizia TISSELLI
  • META TYROSINE DERIVATIVES AS RHO-KINASE INHIBITORS
    Publication number: 20200377500
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are meta tyrosine derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 12, 2018
    Publication date: December 3, 2020
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Christine EDWARDS, Gurdip BHALAY, Patrizia TISSELLI
  • TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS
    Publication number: 20200079774
    Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: October 18, 2019
    Publication date: March 12, 2020
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Anna Maria CAPELLI, David Edward CLARK, Patrizia TISSELLI, Christine EDWARDS, Gurdip BHALAY, Arnaud Jean Francois Auquste CHEGUILLAUME
  • Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors
    Patent number: 10584128
    Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: March 10, 2020
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay
  • Tyrosine amide derivatives as Rho-kinase inhibitors
    Patent number: 10501461
    Abstract: Tyrosine amide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: December 10, 2019
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume
  • TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS
    Publication number: 20180215758
    Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: January 30, 2018
    Publication date: August 2, 2018
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay, Arnaud Jean Francois Auguste Cheguillaume
  • BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO- KINASE INHIBITORS
    Publication number: 20180170939
    Abstract: Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 21, 2017
    Publication date: June 21, 2018
    Applicant: CHIESI FARMACEUTISI S.p.A.
    Inventors: Alessandro Accetta, Fabio Rancati, Anna Maria Capelli, David Edward Clark, Patrizia Tisselli, Christine Edwards, Gurdip Bhalay
  • PYRAZINE DERIVATIVES AS ENAC BLOCKERS
    Publication number: 20170143705
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: December 5, 2016
    Publication date: May 25, 2017
    Inventors: Gurdip BHALAY, Lee EDWARDS, Catherine HOWSHAM, Peter HUNT, Nichola SMITH
  • Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
    Patent number: 9643983
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: May 9, 2017
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Emma Budd, Graham Charles Bloomfield, Stephen Paul Collingwood, Andrew Dunstan, Lee Edwards, Peter Gedeck, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt, Paul Oakley, Nichola Smith
  • Pyrazine derivatives as ENaC blockers
    Patent number: 9522149
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: December 20, 2016
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Lee Edwards, Catherine Howsham, Peter Hunt, Nichola Smith
  • TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES
    Publication number: 20160068546
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: September 8, 2015
    Publication date: March 10, 2016
    Applicant: Novartis AG
    Inventors: Gurdip BHALAY, Emma BUDD, Graham Charles BLOOMFIELD, Stephen Paul COLLINGWOOD, Andrew DUNSTAN, Lee EDWARDS, Peter GEDECK, Catherine HOWSHAM, Peter HUNT, Thomas Anthony HUNT, Paul OAKLEY, Nichola SMITH
  • Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
    Patent number: 9139586
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: September 22, 2015
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Emma Budd, Graham Charles Bloomfield, Stephen Paul Collingwood, Andrew Dunstan, Lee Edwards, Peter Gedeck, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt, Paul Oakley, Nichola Smith
  • PYRAZINE DERIVATIVES AS ENAC BLOCKERS
    Publication number: 20150224098
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: April 20, 2015
    Publication date: August 13, 2015
    Inventors: Gurdip BHALAY, Lee EDWARDS, Catherine HOWSHAM, Peter HUNT, Nichola SMITH
  • Pyrazine derivatives as ENaC blockers
    Patent number: 9050339
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Lee Edwards, Catherine Howsham, Peter Hunt, Nichola Smith
  • IP receptor agonist heterocyclic compounds
    Publication number: 20140357641
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Gurdip Bhalay, Steven Carl Chatlton, Mark Patrick Healy, Catherine Leblanc, Stephen Carl McKeown
  • TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES
    Publication number: 20140171421
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: Gurdip Bhalay, Emma Budd, Graham Charles Bloomfield, Stephen Paul Collingwood, Andrew Dunstan, Lee Edwards, Peter Gedeck, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt, Paul Oakley, Nichola Smith